What type of study is this?

This is a Cross-Sectional Study study.

September 19, 2025

Abstract A165: Restrictive eligibility criteria impacts racial/ethnic enrollment in oncology therapeutic clinical trials: Findings from a large urban California institute

Key Points

Restrictive clinical trial eligibility significantly lowers enrollment of racial/ethnic minorities.
The analysis included 144 clinical trials, with restrictive criteria affecting 20% of studies, showing a notable impact on minority enrollment rates.
Using multivariable mixed-effects logistic regression, the study found that restrictive criteria reduced minority enrollment odds by 45%.
Broadening enrollment eligibility can help reduce racial/ethnic disparities and improve the generalizability of clinical findings.

Abstract

Abstract Background: To increase the number of people eligible for oncology clinical trials (CT) and improve their generalizability, ASCO and Friends of Cancer Research published recommendations in 2017 to broaden the CT eligibility criteria. NCI used these recommendations as the basis for the Experimental Therapeutics Clinical Trial Network protocols. The broadened CT criteria includes people with stable brain metastases, infectious disease (HIV and hepatitis B 75th percentile) vs. standard (≤75th) CTs. Using the NIH underrepresented minority population, we classified our outcome as minority (Hispanic/Black/American Indian/Alaska Native/Native Hawaiian/Pacific Islander) vs non-minority. We used multivariable mixed-effects logistic regression adjusting for sex, age, trial completed pre- vs. post-ASCO 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr A165.

AI से पूछें

Bookmark